Insider Selling: Solid Biosciences (NASDAQ:SLDB) Insider Sells 28,335 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Gabriel Brooks sold 28,335 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $182,477.40. Following the transaction, the insider owned 96,708 shares in the company, valued at approximately $622,799.52. This represents a 22.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Gabriel Brooks also recently made the following trade(s):

• On Monday, February 2nd, Gabriel Brooks sold 28,335 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total value of $182,477.40.

Solid Biosciences Price Performance

Solid Biosciences stock traded down $0.03 during midday trading on Monday, hitting $6.43. 1,032,732 shares of the company were exchanged, compared to its average volume of 984,289. The company has a market cap of $500.96 million, a PE ratio of -2.58 and a beta of 2.67. Solid Biosciences Inc. has a fifty-two week low of $2.41 and a fifty-two week high of $7.37. The company’s fifty day moving average price is $5.75 and its 200-day moving average price is $5.71.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, analysts expect that Solid Biosciences Inc. will post -2.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SLDB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Wall Street Zen cut Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Chardan Capital reissued a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research note on Tuesday, November 4th. JPMorgan Chase & Co. cut their price target on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research report on Wednesday, January 14th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.70.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Analysts maintain a constructive view — SLDB has an average analyst rating of “Moderate Buy,” which may support demand despite near-term weakness. Analyst Rating Article
• Neutral Sentiment: Technical/market context is mixed — trading volume is slightly above average and the share price is within its 52-week range ($2.41–$7.37), suggesting limited directional conviction from broader market participants. (Market data referenced.)
• Negative Sentiment: Large, concurrent insider selling — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan and other insiders) sold sizable positions on Feb 2 at an average price of $6.44. Combined disclosed sales total roughly 226k shares for about $1.45M, with individual position reductions in the ~20–25% range — a signal that could weigh on investor sentiment and share demand. Representative SEC filings: CEO Filing CTO Filing

Institutional Investors Weigh In On Solid Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. AQR Capital Management LLC bought a new stake in Solid Biosciences in the first quarter worth approximately $418,000. Goldman Sachs Group Inc. raised its holdings in Solid Biosciences by 32.2% during the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock valued at $667,000 after buying an additional 43,910 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Solid Biosciences during the 1st quarter worth about $2,338,000. Blair William & Co. IL acquired a new stake in Solid Biosciences in the 2nd quarter worth approximately $807,000. Finally, ProShare Advisors LLC bought a new stake in Solid Biosciences during the 2nd quarter valued at approximately $80,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.